Germline PTEN mutation Cowden syndrome: An underappreciated form of hereditary kidney cancer

Journal of Urology

Volumn 190, Issue 6, 2013, Pages 1990-1998

  Shuch, Brian ^a   Ricketts, Christopher J ^a   Vocke, Cathy D ^a   Komiya, Takefumi ^a   Middelton, Lindsay A ^a   Kauffman, Eric C ^a   Merino, Maria J ^b   Metwalli, Adam R ^a   Dennis, Phillip ^c   Marston Linehan, W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma, renal cell; Genetic diseases, inborn; Hamartoma syndrome, multiple

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; COWDEN SYNDROME; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; MACROCEPHALY; MALE; PRIORITY JOURNAL;

EID: 84888638512     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.06.012     Document Type: Article

References (29)

1. Linehan WM, Srinivasan R and Schmidt LS: The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010;7:277.
2. Linehan WM: Genetic basis of kidney cancer: role of genomics for the development of diseasebased therapeutics. Genome Res 2012;22:2089.
3. Vanharanta S, Buchta M, McWhinney SR et al: Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004;74:153.
4. Ricketts C, Woodward ER, Killick P et al: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008;100:1260.
5. Bertolotto C, Lesueur F, Giuliano S et al: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94.
6. Lloyd KM and Dennis M: Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963;58:136.
7. Nelen MR, Kremer H, Konings IB et al: Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 1999;7:267.
8. Lynch ED, Ostermeyer EA, Lee MK et al: Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 1997;61:1254.
9. Pilarski R and Eng C: Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004;41:323.
10. Mester JL, Zhou M, Prescott N et al: Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome. Urology 2012;79:1187.
11. Eble J, Sauter G and Epstein J: Pathology and Genetics. Lyon, France: International Agency for Research on Cancer 2004.
12. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A et al: A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 2002;100:476.
13. Mester J and Eng C: Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med 2012;14:819.
14. Tan MH, Mester J, Peterson C et al: A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011;88:42.
15. Schmidt L, Junker K, Weirich G et al: Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998;58:1719.
16. Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell 2008;133:403.
17. Pavlovich CP, Walther MM, Eyler RA et al: Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002;26:1542.
18. Crino PB, Nathanson KL and Henske EP: The tuberous sclerosis complex. N Engl J Med 2006;355:1345.
19. Gill AJ, Pachter NS, Chou A et al: Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 2011;35:1578.
20. Merino MJ, Torres-Cabala C, Pinto P et al: The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007;31:1578.
21. Ricketts CJ, Shuch B, Vocke CD et al: Succinate dehydrogenase kidney cancer: an aggressive example of the warburg effect in cancer. J Urol 2012;188:2063.
22. Vocke CD, Yang Y, Pavlovich CP et al: High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 2005;97:931.
23. Yang Y, Padilla-Nash HM, Vira MA et al: The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway. Cancer Genet Cytogenet 2008;180:100.
24. Chen S, Sanford CA, Sun J et al: VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis 2010;13:59.
25. Frew IJ, Thoma CR, Georgiev S et al: pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008;27:1747.
26. Konishi H, Mohseni M, Tamaki A et al: Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A 2011;108:17773.
27. Abou YT, Fahmy MA, Koumakpayi IH et al: The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011;117:290.
28. Cho D, Signoretti S, Dabora S et al: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5:379.
29. Squarize CH, Castilho RM and Gutkind JS: Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008;68:7066.